Abstract:Abstract Background Charcot–Marie–Tooth disease type 1A (CMT1A) is a rare, orphan, hereditary neuromuscular disorder with no cure and for which only symptomatic treatment is currently available. A previous phase 2 trial has shown preliminary evidence of efficacy for PXT3003 in treating CMT1A. This phase 3, international, randomized, double-blind, placebo-controlled study further investigated the efficacy and safety of high- or low-dose PXT3003 (baclofen/naltrexone/D-sorbitol [mg]: 6/0.70/210 or 3/0.35/105) in treating subjects with mild to moderate CMT1A. Methods In this study, 323 subjects with mild-to-moderate CMT1A were randomly assigned in a 1:1:1 ratio to receive 5 mL of high- or low-dose PXT3003, or placebo, orally twice daily for up to 15 months. Efficacy was assessed using the change in Overall Neuropathy Limitations Scale total score from baseline to months 12 and 15 (primary endpoint). Secondary endpoints included the 10-m walk test and other assessments. The high-dose group was discontinued early due to unexpected crystal formation in the high-dose formulation, which resulted in an unanticipated high discontinuation rate, overall and especially in the high-dose group. The statistical analysis plan was adapted to account for the large amount of missing data before database lock, and a modified full analysis set was used in the main analyses. Two sensitivity analyses were performed to check the interpretation based on the use of the modified full analysis set. Results High-dose PXT3003 demonstrated significant improvement in the Overall Neuropathy Limitations Scale total score vs placebo (mean difference: − 0.37 points; 97.5% CI [− 0.68 to − 0.06]; p = 0.008), and consistent treatment effects were shown in the sensitivity analyses. Both PXT3003 doses were safe and well-tolerated. Conclusion The high-dose group demonstrated a statistically significant improvement in the primary endpoint and a good safety profile. Overall, high-dose PXT3003 is a promising treatment option for patients with Charcot–Marie–Tooth disease type 1A.

Challenges in Treating Charcot-Marie-Tooth Disease and Related Neuropathies: Current Management and Future Perspectives

Gene therapy and other novel treatment approaches for Charcot-Marie-Tooth disease

Updated review of therapeutic strategies for Charcot-Marie-Tooth disease and related neuropathies

Will new investigational drugs change the way we treat Charcot-Marie-Tooth disease?

Recent advances in the treatment of Charcot‐Marie‐Tooth neuropathies

Emerging Therapies for Charcot-Marie-Tooth Inherited Neuropathies

New developments in Charcot-Marie-Tooth neuropathy and related diseases

Genetic approaches and pathogenic pathways in the clinical management of Charcot-Marie-Tooth disease

Current Treatment Methods for Charcot–Marie–Tooth Diseases

Charcot-Marie-tooth disease type 2A: An update on pathogenesis and therapeutic perspectives

Charcot-Marie-Tooth: From Molecules to Therapy

Axonal Charcot-Marie-Tooth Disease: from Common Pathogenic Mechanisms to Emerging Treatment Opportunities

L-3-n-Butylphthalide Protects HSPB8 K141N Mutation-Induced Oxidative Stress by Modulating the Mitochondrial Apoptotic and Nrf2 Pathways

Understanding Genetic Pathways, Disease Models, and Potential Therapeutic Approaches

Gene therapies for CMT neuropathies: from the bench to the clinic

Clinical trials in Charcot-Marie-Tooth disorders: a retrospective and preclinical assessment

Development of Improved HDAC6 Inhibitors as Pharmacological Therapy for Axonal Charcot–Marie–Tooth Disease

CMT2D neuropathy is linked to the neomorphic binding activity of glycyl-tRNA synthetase

Aberrant GlyRS-HDAC6 Interaction Linked to Axonal Transport Deficits in Charcot-Marie-Tooth Neuropathy

Advances in the Study of Genetic Characteristics and Molecular Mechanisms in Charcot-Marie-Tooth Disease

A double-blind, placebo-controlled, randomized trial of PXT3003 for the treatment of Charcot–Marie–Tooth type 1A